Faruqi & Faruqi Investigates Rezolute Losses

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 5d ago

0mins

RZLT+6.85%

Should l Buy RZLT?

Source: Globenewswire

Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. after its stock plummeted on December 11, 2025, due to disappointing clinical trial results, leading to significant investor losses.
Clinical Trial Failure: The Phase 3 sunRIZE clinical trial for Rezolute's lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints, severely impacting the drug's market prospects and investor confidence.
Significant Investor Losses: As the trial results did not show statistical significance, Rezolute's stock price sharply declined, potentially resulting in millions of dollars in losses for investors, prompting Faruqi & Faruqi to encourage affected investors to discuss their legal options.
Law Firm Background: Founded in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors and has offices in New York, Pennsylvania, California, and Georgia, committed to protecting investor rights.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.

RZLT

$3.12+Infinity%1D

Analyst Views on RZLT

Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Analyst Rating

5 Buy

4 Hold

0 Sell

Moderate Buy

Current: 2.920

Low

2.00

Averages

6.29

High

20.00

Current: 2.920

Low

2.00

Averages

6.29

High

20.00

Wedbush

Neutral

maintain

$1 -> $2

2026-01-08

Reason

Wedbush

Price Target

$1 -> $2

AI Analysis

2026-01-08

maintain

Neutral

Reason

Wedbush raised the firm's price target on Rezolute to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and detailed glycemic control outcomes from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism. Wedbush believes that the new data demonstrates ersodetug's activity in modulating insulin receptors to reduce both events and time in hypoglycemia in treated patients, although whether the magnitude of benefit is sufficient to support an FDA approval remains unclear.

Guggenheim

Buy

downgrade

$15 -> $6

2025-12-12

Reason

Guggenheim

Price Target

$15 -> $6

2025-12-12

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Rezolute to $6 from $15 and keeps a Buy rating on the shares. Following the failure of the sunRIZE trial, the firm is eliminating cHI from its model despite managment's "optimism" on a potential path forward, the analyst tells investors. The firm's lower target reflects the elimination of cHI, a lower price point forecast for tHI and lower odds of success, until proven otherwise, for tHI, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RZLT

Unlock Now

About RZLT

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Faruqi & Faruqi Investigates Losses in Rezolute Stock

1 day agoPRnewswire

Stock Price Plunge: Rezolute, Inc. shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, reflecting an 85-90% drop and investor disillusionment with the company's prospects.
Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, urging investors who suffered significant losses to contact partner Josh Wilson directly, indicating the firm's commitment to protecting investor rights.
Clinical Trial Failure: The lead drug candidate ersodetug failed to meet both primary and key secondary endpoints in clinical trials, leading to a significant decline in market confidence and the potential for increased legal actions against the company.
Investor Rights Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law and aiming to provide legal support for affected investors.